Gary Morrow, Pioneer in Cancer Research and Symptom Care, Dies at 82

Dr. Gary R. Morrow, a foundational figure in cancer supportive care and a longstanding leader at the University of Rochester Medicine Wilmot Cancer Institute, died on July 7, 2026, at age 82, following complications from pneumonia after living with prostate cancer for 16 years. His pioneering work established the scientific basis for controlling chemotherapy-induced nausea and vomiting.

In Plain English: The Clinical Takeaway

• Supportive Care Pioneer: Dr. Morrow shifted clinical focus toward managing treatment side effects like nausea, improving quality of life for millions of patients globally.
• Anti-Emetic Protocols: His research directly supported the necessity of anti-emetic medications (drugs that prevent nausea and vomiting) during chemotherapy regimens.
• Biopsychosocial Integration: Trained in clinical psychology, he successfully integrated psychological and social factors into oncology, anticipating modern patient-centered care.

Transforming Cancer Care From the Sidelines to Center Stage

During a career spanning nearly 50 years at the University of Rochester, Dr. Morrow tackled issues that were often overlooked by an oncology field historically fixated purely on tumor biology. According to the American Society of Clinical Oncology (ASCO), his groundbreaking research contributing to the implementation of anti-emetic drugs ranks among the top five most important advances in cancer care over the past 50 years. By moving symptom-management research out of the shadows, he fundamentally altered how clinicians approach the patient experience.

“Facing up to the fact that medicine doesn’t have all the answers and turning that into an opportunity was very important,” said Hucky Land, PhD, Wilmot deputy director. “Gary has done that against all odds. It is a very rare achievement.”

Building a Legacy of Mentorship and Funding

Dr. Morrow secured approximately $100 million in research funding over his tenure at the University of Rochester. Beyond financial metrics, his leadership shaped generations of clinical investigators whom he affectionately termed his “grasshoppers.” Many of these trainees now hold prominent leadership roles within the Wilmot Cancer Institute, including Dr. Karen Mustian, Dr. Supriya Mohile, Dr. Charles Kamen, and Dr. Michelle Janelsins, who holds the Joan and Gary Morrow Distinguished Professorship for Supportive Care in Cancer.

“Gary was very demanding in a good sense,” said David Linehan, MD, CEO of University of Rochester Medicine and Dean of the School of Medicine and Dentistry. “He was always fighting for what he believed in.”

Key Milestones in Dr. Gary R. Morrow’s Career

Metric / Milestone	Detail
Tenure Length	Nearly 50 years at the University of Rochester
Research Funding	Generated approximately $100 million in grants
Clinical Focus	Chemotherapy-induced nausea, vomiting, and supportive care
Core Framework	Application of the biopsychosocial model to oncology

Contraindications & When to Consult a Doctor

A Lasting Impact on Global Oncology

By applying the biopsychosocial model to oncology, he proved that ameliorating toxic side effects directly preserves a patient's ability to tolerate life-saving therapy. His framework remains a pillar of contemporary supportive oncology worldwide.

Photo: urmc.rochester.edu

References

• The ASCO Post. “Dr. Gary R.
• American Society of Clinical Oncology (ASCO).

Disclaimer: This article is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment.